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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.09.014Objective: Atrial fibrillation remains one of the most common postoperative com-
plications of coronary artery bypass grafting. Despite many clinical studies, there is
still no consensus regarding the best prevention strategy for atrial arrhythmia. A
randomized, double-blind, placebo-controlled trial was conducted to determine the
effect of steroids on the occurrence of atrial fibrillation after elective coronary artery
bypass grafting.
Methods: Eighty-eight consecutive patients were prospectively entered in this study.
No patient had documented or suspected arrhythmias before surgery. Forty-three
patients received 1 g of methylprednisolone before surgery and 4 mg of dexameth-
asone every 6 hours for 1 day after surgery, and 43 patients received only placebo.
The primary end point was the overall occurrence of postoperative atrial fibrillation.
Results: Postoperative atrial fibrillation occurred in 9 (21%) of the 43 patients in the
steroid group, as compared with 22 (51%) of the 43 patients in the placebo group
(P  .003). Minor postoperative complications occurred in 15 steroid patients
(35%) and in 6 patients (14%) receiving placebo (P .01). Major complications
occurred in 4 patients who received steroids (9%) and in 2 patients (5%) who
received placebo (P  .68; for all complications, P  .05).
Conclusions: Prophylactic short-term steroid administration in patients undergoing
coronary artery bypass grafting significantly reduced postoperative atrial fibrillation.
In this study, there was no significant difference between the steroid group and the
placebo group with regard to the length of hospital stay; however, the steroid group
had more complications, which may contribute to prolonged hospitalization.
Atrial fibrillation is a common complication of cardiac surgery during thefirst postoperative week, with an occurrence ranging from 20% to 50% ofpatients undergoing coronary artery bypass grafting (CABG).1-8 The patho-
physiologic mechanism of postoperative atrial fibrillation remains unknown; how-
ever, a multifactorial etiology is likely. These mechanisms include increased cat-
echolamines; acute atrial distention or inflammation from the trauma of the
operation; alteration in autonomic tone from the operation and the stress of the
postoperative period; ischemic injury to the atria as a result of the operation or
inadequate protection during cardiopulmonary bypass (CPB); electrolyte and vol-
ume shifts during CPB, resulting in changes in repolarization; inflammation result-
ing from pericarditis; and a variety of other electrophysiologic changes that may
occur as a result of the CPB procedure, the cardioplegia, or the operation itself, all
of which may result in a lower atrial fibrillation threshold.6,7,9,10
A variety of pharmacologic agents have been used to prevent the occurrence of
atrial fibrillation, including -adrenergic blockers, amiodarone, and magne-
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erative atrial fibrillation and the well-known inflammatory
response to CPB, steroids with the ability to inhibit inflam-
matory mediators—including interleukin (IL)-6, IL-8, tu-
mor necrosis factor (TNF)-, leukotriene B4, and tissue
plasminogen activator—might have a beneficial effect in
decreasing postoperative atrial fibrillation after CABG. The
purpose of this study was to assess the use of short-term
steroids as prophylaxis against atrial fibrillation after
CABG.
Methods
From August 1, 2000, to February 28, 2001, 88 patients were
screened and randomized for participation in this study. In-
clusion criteria consisted of informed consent, age greater
than 18 years, elective first-time CABG, -adrenergic block-
ade, and normal sinus rhythm. Exclusion criteria included a
history of heart block; a permanent pacemaker; any docu-
mented or suspected supraventricular or ventricular arrhyth-
mias, including isolated atrial or ventricular premature depo-
larization noted on preoperative surface electrocardiography;
requirement for additional procedures, such as valvular opera-
tion or left ventricular aneurysmectomy; refusal to participate in
this study; use of a radial artery for grafting; steroid depen-
dency; steroid allergy; and participation in another investiga-
tional protocol.
In a supplementary component of the study, we measured
the cytokine concentrations and compared the measurements
between groups. Concentrations of TNF-, IL-6, IL-8, and
IL-10 were measured with enzyme-linked immunosorbent assay
at 4 and 24 hours after surgery in a subset of 22 patients in the
steroid group and in 86 similarly treated control patients. Stan-
dard enzyme-linked immunosorbent assay measurements were
made by using capture and detection antibodies obtained from
Pharmingen (San Diego, Calif) that for TNF- were 18631D 2
g/mL and 18642D 1 g/mL, for IL-6 were 18871D 1 g/mL
and 18882D 1 g/mL, for IL-8 were 20781D 1 g/mL and
20792D 1 g/mL, and for IL-10 were 20701D 1 g/mL and
18562D 1 g/mL.
Study Protocol
The study design was approved by the Clinical Research Ethics
Board of the University of British Columbia/Providence Health
Care and was a double-blind protocol in which the surgical staff,
principal investigators, and patients were blinded to the assigned
therapy. Clinical data were collected and recorded in the database
by independent blinded investigators.
Patients were randomly assigned in a double-blind fashion
either to a placebo group receiving maintenance fluids (5% dex-
trose water with potassium chloride 20 mEq/L) or to a steroid
group receiving 1 g of intravenous methylprednisolone sodium
succinate (Solu-Medrol; Upjohn, Kalamazoo, Mich) before CPB
and 4 mg of intravenous dexamethasone (Decadron; Merck Sharp
& Dohme, West Point, Pa) every 6 hours for a total of 4 doses in
the first 24 hours after surgery. All vials of the steroid and placebo
medications were prepared and randomized by the hospital phar-
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Operative Technique
Standardized anesthesia and surgical protocols were applied in all
cases. All operations were performed by using normothermic
(37°C) CPB with antegrade warm-blood cardioplegia. CPB was
performed with aortic and right atrial cannulation, membrane
oxygenation, and nonpulsatile flow. Standard surgical techniques
were used to create the distal coronary anastomoses first; proximal
anastomoses followed for saphenous vein grafts, and internal tho-
racic artery grafts were conducted after distal venous anastomoses.
After weaning from CPB, inotropic support was initiated when
needed to maintain cardiac contractility, if the cardiac index was
less than 2 L · min · m2, or if the mean arterial pressure was less
than 70 mm Hg. Electrical pacing was instituted (atrial or atrio-
ventricular) when needed to maintain a heart rate greater than 70
beats/min. Patients were continuously monitored in the cardiac
surgery intensive care unit. Patients were weaned off mechanical
ventilation on the basis of hemodynamic stability, blood gas anal-
ysis, and level of alertness. Discharge from the cardiac surgery
intensive care unit was generally accomplished after extubation
and the discontinuation of all vasoactive medications.
Patients receiving  blockade, digitalis, or calcium channel
blockade had these medications continued until the day of opera-
tion. Standard postoperative medications were incorporated. Pa-
tients received the usual postoperative cardiac care, including 
blockade to prevent atrial arrhythmias as a standard protocol.
Hemodynamic Measurement and Monitoring
Patients were continuously monitored in the cardiac surgery inten-
sive care unit with arterial, central venous, and pulmonary artery
pressure monitoring and thermodilution cardiac output determina-
tion. Cardiac rhythm was continuously monitored in the intensive
care unit with bedside monitors and on the ward, after the intensive
care unit until discharge, with telemetry.
Twelve-lead electrocardiograms were obtained immediately af-
ter surgery and on the first morning after the operation. Supraven-
tricular and ventricular arrhythmias and their respective treatment
interventions were documented and supported by the inclusion of
rhythm strips in the patients’ charts. The investigator reviewed all
rhythm strips daily until the patients were discharged from the
hospital. For the purpose of defining end points in this study,
postoperative atrial fibrillation was defined as an irregularly irreg-
ular supraventricular rhythm present in the absence of P waves that
required treatment and that was typically sustained for more than
15 minutes.
Episodes of atrial fibrillation were considered when they re-
curred or continued into the following 24-hour period as an addi-
tional episode. Arrhythmia data were collected and recorded for
the first 7 postoperative days.
According to these definitions, cardiac arrhythmias were
treated under the direction of the attending surgeon. Standardized
protocols for the treatment of supraventricular and ventricular
arrhythmias were adhered to during the study. Blood gas abnor-
malities were corrected. Potassium, magnesium, and calcium were
administered as needed to maintain serum concentrations greater
than 4 mmol/L, 1.5 mEq/L, and 8.5 mg/dL, respectively. Thera-
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included standard pharmacologic management and electric cardio-
version if indicated.
Patients were routinely anticoagulated with heparin, warfa-
rin, or both when atrial fibrillation persisted for longer than 36
hours. Patients were followed up with a routine protocol on the
ward until discharge from the hospital. The length of hospital
stay was calculated from the day of operation until the day of
discharge.
Statistics
The null hypothesis was that there was no difference in the
occurrence of postoperative atrial fibrillation between therapy with
short-term steroids and placebo. With the occurrence of postoper-
ative atrial fibrillation after CABG in our hospital of 43.5%, a
sample size of 168 patients was estimated to be sufficient to detect
a 50% reduction in the steroid treatment group with a power of
80% and a 2-sided type I error of 0.05. The primary end point was
the occurrence of postoperative atrial fibrillation. Secondary end
points were the length of hospital stay and the adverse effects
(complications) of steroids.
Comparison of continuous variables across the 2 treatment
groups was accomplished with a 2-sample t test or a Wilcoxon
rank sum test where appropriate. Comparison of categorical vari-
ables across the 2 groups was analyzed with 2 or Fisher exact
tests (where applicable). A logistic regression analysis was per-
formed to compare the 2 groups with possible confounders ad-
justed. The cytokine data analysis was conducted with log trans-
formation by 2-way analysis of variance: 1 way with repeated
measures (2 cytokine time points) and the other way between
groups (steroid or not).
Statistical analysis was performed with SAS software (SAS
Institute, Cary, NC). The frequencies were presented with the 95%
confidence limits (CL).
Interim Analysis
A planned interim analysis was performed after 50% enrollment to
assess prospectively determined criteria for termination. This anal-
ysis revealed that the difference in the primary outcome variable
between treatment groups had crossed the statistical boundary for
breaking the code interim analysis. The analysis revealed a signif-
icant reduction of the occurrence of postoperative atrial fibrillation
after CABG in the steroid group and revealed no identified detri-
mental effect of the steroid. Therefore, study enrollment was
terminated on February 28, 2001; 88 patients had been randomly
assigned to the groups, and the code was broken. Medical history,
demographic data, and clinical course data were collected for each
patient. Criteria for termination of the study were based on the
O’Brien-Fleming spending function, the P value for the interim
analysis was .005, and the P value for the final analysis for all
patients was .048.
Results
This randomized, prospective clinical trial was performed in
88 patients: 2 patients were excluded from the study be-
cause they had off-pump CABG surgery, 43 patients re-
ceived a steroid, and 43 patients received placebo. Selected
The Journal of Thoracpatient demographics are presented in Table 1. Statistically
significant differences were found in age and left ventricular
ejection fraction between groups. Other variables were not
different between treatment groups. There were no deaths in
the study period.
Postoperative Atrial Fibrillation
The percentages of the occurrence of postoperative atrial
fibrillation in patients in both groups are shown in Table 2.
The occurrence of postoperative atrial fibrillation was
20.93% (95% CL, 8.77%-33.09%; 9 of 43 patients) in the
short-term steroid group, as compared with 51.16% (95%
CL, 36.22%-66.1%; 22 of 43 patients) in the placebo group
(P  .003).
Length of Hospital Stay
Patients with normal sinus rhythm had a shorter length of
hospital stay than those with atrial fibrillation (median, 6 vs
TABLE 1. Clinical characteristics of the steroid and pla-
cebo groups
Variable Steroid group Placebo group P value
No. 43 43
Sex (F/M) 10/33 10/33 1.0
Age (y) 67.2 (64.5-70) 61.7 (58.6-64.8) .007
History of MI 28 28 1.0
Asthma 6 1 .11
COPD 10 6 .27
CHF 9 11 .61
HTN 27 23 .38
Smoking 17 17 1.0
CRF 2 2 1.0
LVEF 37.8 (20-71) 49.2 (20-74) .03
Crossclamp
time
66 (57-75) 71 (62-80) .39
Atrial pacing 8 13 .21
Atrioventricular
pacing
7 1 .06
MI, Myocardial infarction; COPD, chronic obstructive pulmonary disease;
CHF, congestive heart failure; HTN, hypertension; CRF, chronic renal fail-
ure; LVEF, left ventricular ejection fraction. Age, LVEF, and crossclamp time
are given as mean (range).
TABLE 2. Incidence of postoperative atrial fibrillation (AF)
in the steroid and placebo groups
Group
Patients, n (%)
TotalNo AF AF
Steroid* 34 (79.1%) 9 (20.9%) 43
Placebo 21 (48.8%) 22 (51.2%) 43
Total 55 31 86
*P  .003.8 days, respectively; P  .002). However, there was no
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stay between the 2 groups (median of 6 days in the steroid
group as compared with 7 days in the placebo group;
P  .34).
Complications
Major complications included severe sternal infection re-
quiring rewiring, acute pancreatitis, and perforated gastric
ulcer. Minor complications are listed in Table 3.
The data analysis showed that the steroid group had more
minor complications (34.88%; 95% CL, 23.19%-53.73%)
than the placebo group (13.95%; 95% CL, 3.82%-25.42%)
(P  .01), but there was no statistically significant differ-
ence in major complications (9.3%; 95% CL, 0.62%-
17.98% vs 4.65%; 95% CL, 0%-10.95%, respectively) (P
.68) or overall postoperative complications (overall P 
.053; Tables 3 and 4).
There was a significant difference in the white blood cell
count at 12 and 24 hours after surgery. It was apparent that
the steroid group had higher white blood cell counts at 12
TABLE 3. Complications in the steroid and placebo groups
Variable
Steroid
group
Placebo
group
GI disturbance 4 1
High blood sugar 4 —
Mental confusion 2 2
Increased postoperative creatinine 1 1
UTI 2 —
Sternal wound infection 1 1
Leg wound infection 1 1
Intravenous line infection 1 —
Gastritis — 1
Sternal dehiscence* 2 2
Acute pancreatitis* 1 —
Perforated GU* 1 —
GI, Gastrointestinal; UTI, urinary tract infection; GU, gastric ulcer. *Major
complications (some patients had more than 1 complication).
TABLE 4. Major and minor complications in the steroid
and placebo groups
Group
Complications, n (%)
TotalNone Major Minor
Steroid 24 (55.8%) 4 (9.3%) 15 (34.88%) 43
Placebo 35 (81.4%) 2 (4.65%) 6 (13.95%) 43
Total 59 6 21 86
Minor complications, P  .01; major complications, P  .68; overall
complications, P  .05.and 24 hours (median, 6.5 and 8.45 G/L, respectively) than
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 .0001).
Cytokine Measurement
The concentrations of TNF-, IL-8, and IL-10 at 4 and 24
hours after surgery were not statistically significantly dif-
ferent between the steroid and control groups. However, the
steroid group had significantly reduced IL-6 concentrations
at both 4 and 24 hours after surgery compared with controls.
At 4 hours, IL-6 in the steroid group was 593.2  95.5
pg/mL versus 1206.8  255.6 pg/mL in the control group
(P  .04), and at 24 hours IL-6 in the steroid group was
316.6  64.2 pg/mL versus 570.7  68.2 pg/mL in the
control group (P  .01). The difference of IL-6 with time
had a P value of less than .001, and the difference in IL-6
between the steroid group and nonsteroid group had a P
value of less than .009.
Discussion
Prophylactic short-term steroid administration in patients
undergoing CABG reduced the occurrence of postoperative
atrial fibrillation by approximately 50%. Because of statis-
tically significant differences in 2 baseline characteristics in
the 2 groups—advancing age and low ejection fraction in
the steroid group, which are considered the risk factors of
postoperative atrial fibrillation—the efficacy of steroids
might be stronger than was evident. Creswell and associ-
ates5 found that advancing age and low ejection fraction
were risk factors of postoperative atrial fibrillation by uni-
variate logistic regression analysis.
Our findings supported the recent report by Yared and
colleagues20 of a lower incidence of new-onset atrial fibril-
lation with the administration of dexamethasone 0.6 mg/kg
after the induction of anesthesia. However, the study by
Halvorsen and colleagues21 showed that dexamethasone (8
mg in divided doses) was beneficial in reducing emetic
symptoms and improving appetite after cardiac surgery but
had no effect on the occurrence of postoperative atrial
fibrillation. This may be explained by the different doses of
corticosteroids administered in each study.
In this study, patients without postoperative atrial fibril-
lation had a shorter length of hospital stay. Overall, there
was no significant difference between the steroid group and
the placebo group with regard to the length of hospital stay.
Data showed that the steroid group had more complications,
which may contribute to prolonged hospitalization.
Although there was statistically significant difference in
minor complications between the steroid group and the
placebo group, there was no statistically significant differ-
ence in major and overall complications. However, there
was a trend toward more complications in the steroid group.
In this study, 4 patients had high glucose intolerance that
necessitated consultation with an endocrinologist to control
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cose intolerance was worsened by steroids during CPB. This
might be a disadvantage of steroid use.
Infection is another complication that can be a concern
with steroid administration. In this study, we found infec-
tion in both groups, with no statistically significant differ-
ence. The white blood cell count was increased significantly
in the steroid group at 12 and 24 hours after surgery.
However, the white blood cell count 5 days after surgery
had returned to the preoperative level. This can be explained
by the demargination process of white blood cells, which
could be effected by the steroid.
Many studies have documented the adverse effects of
CPB, and some studies claim an advantage of steroid use in
cardiac surgery.23,24 Jansen and associates25 showed that
steroids could inhibit TNF and leukotriene release, and
these are the primary mediators involved in reperfusion
phenomena and sepsis. In that study, steroids improved the
postoperative course after CPB.
Teoh and associates26 found that steroids decreased cy-
tokine release and the vasodilation effect. Engelman and
colleagues27 found the same result and recommended pro-
phylactic steroid use in open-heart surgery. The dose rec-
ommended by Engelman and colleagues was used in this
study. The steroid doses maintained therapeutic steroid ef-
fects for 4 days, which covers the peak incidence of post-
operative atrial fibrillation. Engelman and colleagues did
not find any adverse effects of steroid use, possibly because
of their small sample size (10 steroid and 9 placebo
patients).
Recent investigations have indicated that cytokines play
a key role in the inflammatory cascade associated with CPB.
The levels of TNF-, IL-6, and IL-8 were correlated with
the duration of cardiac ischemia, and the myocardium is a
major source of these cytokines during CPB.28 Proinflam-
matory cytokines such as IL-6 and IL-8 were associated
with postoperative myocardial dysfunction and the outcome
of cardiac surgery.29 In our study, we found that short-term
steroid administration reduced the IL-6 concentrations at
both 4 and 24 hours after surgery. This might improve the
outcome of cardiac surgery.
The median length of hospital stay for patients with atrial
fibrillation was 8 days, compared with 6 days in patients
with normal sinus rhythm. However, the median length of
hospital stay of the steroid group was 6 days, and in the
placebo group it was 7 days. This could be explained by the
increased length of hospital stay in the steroid group. Two
patients with major complications in the steroid group had
30- and 32-day hospital stays, and this made a significant
difference between patients with and without complications.
In our study, only advanced age was consistently asso-
ciated with an increased risk of postoperative atrial fibril-
lation by multivariate logistic regression analysis. Creswell
The Journal of Thoracand associates5 found that chronic obstructive lung disease
and crossclamp time were the risk factors for the develop-
ment of postoperative atrial fibrillation. This might be re-
lated to the sample sizes (86 vs 4507 patients). Also, we
found that there was no statistically significant difference in
atrial pacing and postoperative atrial fibrillation.
Limitations of the Study
Our study was a double-blind randomized controlled trial,
and the design and reporting of the study were compatible
with the Consolidated Standards of Reporting Trials state-
ment.30 However, there were 2 issues of concern in the
study. As the results showed, steroids conferred a beneficial
effect on the occurrence of postoperative atrial fibrillation
after CABG. There was a slight increase in the postopera-
tive complications; even the P values did not show any
statistically significant difference. Some might say that we
should have continued the study and gathered more data to
evaluate safety and efficacy. However, at the commence-
ment of our study, we decided to perform the interim
analysis, and our primary end point was the occurrence of
postoperative atrial fibrillation.
After 50% enrollment, the code was broken, and the data
showed that the primary outcome was satisfied, so we
agreed to stop the study. It would be appropriate to design
another study to see whether steroids in different dosages
can improve both primary and secondary outcomes. An-
other issue in our study was the cytokine levels. With
limited funding in this study, we could include only 22
patients in the steroid group to compare with the previous
data in a control group. We found in our study that steroids
can inhibit IL-6, which is correlated with the postoperative
outcome in cardiac surgery. However, we did not correlate
IL-6 with the incidence of postoperative atrial fibrillation
after CABG, probably because of the small sample size.
With a larger sample size, we might find some correlation
between postoperative atrial fibrillation and IL-6. That
might be the cause of postoperative atrial fibrillation after
CABG.
In conclusion, with the high degree of efficacy of steroids
in decreasing postoperative atrial fibrillation but with
slightly increased complications, we could try to adjust the
steroid dose (for example, give half the dose of methylpred-
nisolone [500 mg, as given in heart transplant recipients]) or
use prophylactic steroids for patients who are at high risk of
developing postoperative atrial fibrillation, such as older
patients or those with long-crossclamp-time operations, low
ejection fraction, chronic obstructive pulmonary disease,
preoperative use of digoxin, or valvular disease. We could
also use prophylactic steroids with patients who do not have
diabetes mellitus. Subsequently, we can redesign other stud-
ies for prophylactic steroid administration for postoperative
atrial fibrillation, such as high- versus low-dose steroid use,
ic and Cardiovascular Surgery ● Volume 130, Number 1 97
Cardiopulmonary Support and Physiology Prasongsukarn et al
CSPsteroid in patients at high risk for atrial fibrillation, steroid
combined with  blockade, steroid combined with amioda-
rone, and steroid with biatrial pacing. It is hoped that, with
further study, the best prevention for postoperative atrial
fibrillation can be identified.
We appreciate the statistical analysis performed by Lillian Ding
and the word processing performed by Kevin Shillitto.
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